Pathstone Family Office Discloses 1M Share Stake in Cognition Therapeutics
Ticker: CGTX · Form: SC 13G · Filed: Jan 19, 2024 · CIK: 1455365
| Field | Detail |
|---|---|
| Company | Cognition Therapeutics INC (CGTX) |
| Form Type | SC 13G |
| Filed Date | Jan 19, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, SC-13G
TL;DR
**Pathstone Family Office just revealed a 1 million share stake in CGTX, signaling institutional confidence.**
AI Summary
Pathstone Family Office, LLC, a Delaware-organized entity, reported beneficial ownership of 1,000,000 shares of Cognition Therapeutics Inc. (CGTX) common stock as of October 13, 2023. This filing, an SC 13G, indicates that Pathstone holds these shares for investment purposes and not to influence control. This matters to investors because it signals a significant institutional investment in CGTX, potentially boosting confidence in the company's future prospects.
Why It Matters
A substantial institutional investment like this can be seen as a vote of confidence in Cognition Therapeutics, potentially attracting more investors and positively impacting the stock price.
Risk Assessment
Risk Level: low — This filing indicates a passive investment, posing minimal direct risk to current shareholders.
Analyst Insight
Investors might view this institutional stake as a positive signal, potentially warranting further research into Cognition Therapeutics' fundamentals and future prospects.
Key Numbers
- 1,000,000 — Shares Beneficially Owned (Pathstone Family Office's stake in Cognition Therapeutics Inc.)
Key Players & Entities
- Pathstone Family Office, LLC (company) — the reporting person beneficially owning shares
- Cognition Therapeutics Inc. (company) — the subject company whose shares are being reported
- 1,000,000 (dollar_amount) — number of shares beneficially owned
- October 13, 2023 (date) — date of event requiring the filing
Forward-Looking Statements
- Other institutional investors may take note of Pathstone's position and consider investing in Cognition Therapeutics. (Cognition Therapeutics Inc.) — medium confidence, target: Q2 2024
FAQ
Who filed this SC 13G statement?
The SC 13G statement was filed by Pathstone Family Office, LLC, as indicated in the 'FILED BY' section of the filing.
What is the name of the issuer whose securities are being reported?
The name of the issuer is COGNITION THERAPEUTICS INC, as stated under 'SUBJECT COMPANY' and 'Name of Issuer' in the filing.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was October 13, 2023, as specified on the cover page of the Schedule 13G.
What type of securities are covered by this filing?
The filing covers 'Common stock' of Cognition Therapeutics Inc., as stated under 'Title of Class of Securities'.
Under which rule of the Securities Exchange Act of 1934 was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b) of the Securities Exchange Act of 1934, as indicated by the checked box on the cover page.
Filing Stats: 957 words · 4 min read · ~3 pages · Grade level 8.7 · Accepted 2024-01-19 15:07:49
Filing Documents
- cgtx_11824.htm (SC 13G) — 25KB
- 0001085146-24-000333.txt ( ) — 27KB
(a)
ITEM 1(a). NAME OF ISSUER: COGNITION THERAPEUTICS INC
(b)
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: 2403 Sidney Street Pittsburgh, PA 15203
(a)
ITEM 2(a). NAME OF PERSON FILING: This statement is being filed by Pathstone Family Office, LLC, (Pathstone or the Reporting Person). Pathstone is a registered investment adviser under Section 203 of the Investment Advisers Act of 1940. The shares to which this Schedule 13G relates are owned directly by the accounts managed by Pathstone.
(b)
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: 10 Sterling Blvd Suite 402 Englewood, NJ 07631
(c)
ITEM 2(c). CITIZENSHIP: Delaware
(d)
ITEM 2(d). TITLE OF CLASS OF SECURITIES: Common stock
(e)
ITEM 2(e). CUSIP NUMBER: 19243B102 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c); (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); (c) [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); (d) [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8); (e) [X] An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); (k) [ ] Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution: ITEM 4. (a) Amount beneficially owned: 2,205,377 (b) Percent of class: 7.53% (c) Number of shares as to which the person has: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 0 ITEM 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the fol